NewAmsterdam Pharma Announces Issuance Of Composition Of Matter Patent For Obicetrapib By The USPTO
Portfolio Pulse from Benzinga Newsdesk
NewAmsterdam Pharma (NASDAQ:NAMS) has announced the issuance of a new patent for obicetrapib by the USPTO, extending the patent term until July 2043. This development is significant for the company's portfolio of non-statin medicines targeting cardiovascular disease.
June 11, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewAmsterdam Pharma has received a new patent for obicetrapib, extending its term until July 2043. This strengthens the company's intellectual property portfolio and could enhance its market position in cardiovascular disease treatments.
The issuance of a new patent extending until 2043 is a significant positive development for NewAmsterdam Pharma. It strengthens their intellectual property portfolio, potentially enhancing their market position and providing a competitive edge in the cardiovascular disease treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100